Vertex's Phase 1/2 trial of VX-880 for Type 1 Diabetes reduced or eliminated insulin needs and improved glycemic control.

Vertex Pharmaceuticals' Phase 1/2 FORWARD trial of VX-880, a stem cell-derived islet cell therapy, shows promise in treating Type 1 Diabetes (T1D). Results demonstrate that VX-880 reduced or eliminated the need for insulin in patients, improved glycemic control, and reduced severe hypoglycemic events. The trial's expansion to enroll 37 participants aims to generate data for potential future availability of VX-880 to T1D patients.

June 21, 2024
4 Articles